HSDB8198

Vandetanib Fumarate is an orally available tyrosine kinase inhibitor. Vandetanib Fumarate works by blocking RET (REarranged during Transfection), vascular endothelial growth factor receptor (VEGFR-2, VEGFR-3), and epidermal growth factor receptor and to a

Vandetanib trifluoroacetate (D6474 trifluoroacetate) is an orally active and potent VEGFR2 KDR tyrosine kinase inhibitor with an IC50 value of 40 nM. It also inhibits VEGFR3 FLT4 and EGFR HER1, with IC50 values of 110 nM and 500 nM respectively.

Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 (IC50: 40 nM). It also inhibits VEGFR3 and EGFR.

Vandetanib hydrochloride (D6474 hydrochloride) is a potent, orally active inhibitor of VEGFR2 KDR tyrosine kinase activity with an IC50 of 40 nM. It also exhibits activity against VEGFR3 FLT4 tyrosine kinase activity (IC50 = 110 nM) and EGFR HER1 (IC50 = 500 nM) [1].